Comparison of etomidate–midazolam and propofol–midazolam sedation in patients scheduled for esophagogastroduodenoscopy and colonoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004621

Enrollment

200

Registered

2020-01-10

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : active treatment group: midazolan+etomidate control group midazolan+profopol? ??

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20-80 years old male and female 2) Patients who fully understand the purpose of this study and agree to participate in this study. 3) All patients undergoing gastrointestinal endoscopy

Exclusion criteria

Exclusion criteria: 1) If the patient does not agree with the treatment 2) you have severe or uncontrolled heart, lung, kidney, or mental problems : systolic blood pressure <80 mmHg, body temperature> 39 ° C, Pulse oximeter <90%, patients with Chronic obstructive pulmonary disease (COPD), patients with Severe heart failure Severe epilepsy, patients with adrenocortical insufficiency, acute severe infection, and pregnancy 3) Patients who have taken drugs that affect the central nervous system or who have allergy to the study drug, Patients who have used general anesthesia within the last 7 days 4) Patients judged to be inappropriate by other researchers

Design outcomes

Primary

Measure	Time frame
adverse event	—

Secondary

Measure	Time frame
adverse event	—

Countries

Korea, Republic of

Contacts

Public ContactJun-Won Chung

Gachon University Gil Medical Center

Outcome results